Core Viewpoint - BioPorto A/S has pre-announced its key financial results for Q3 2025, showing continued growth in NGAL sales, while also revising its full-year guidance for 2025 downward due to performance in the first nine months of the year [1][6]. Financial Performance - Total revenue for the first nine months of 2025 reached DKK 28.7 million, a 1% increase year-over-year, with a 2% increase at constant exchange rates [3]. - NGAL sales increased by 5% compared to the same period in 2024, and by 7% at constant exchange rates, primarily driven by US NGAL RUO sales and ProNephro AKI sales [3]. - US NGAL RUO sales surged by 21% year-over-year, and by 23% at constant exchange rates [3]. - Revenue for Q3 2025 totaled DKK 10.4 million, reflecting a 7% increase compared to Q3 2024, and a 10% increase at constant exchange rates [9]. - Adjusted EBITDA loss for the first nine months of 2025 was DKK 63.3 million, compared to DKK 51.1 million in the same period last year [4]. Sales Breakdown - Q3 2025 NGAL sales in the US amounted to DKK 4.7 million, a 20% increase from Q3 2024, while ROW NGAL sales plummeted by 87% to DKK 0.4 million [5]. - ProNephro AKI sales through distributors in Q3 2025 were DKK 2.1 million [9]. - Total NGAL sales for the first nine months of 2025 were DKK 19.3 million, a 5% increase from the previous year [5]. Guidance Adjustment - The full-year revenue guidance for 2025 has been revised to a range of DKK 40-45 million, down from the previous estimate of DKK 45-50 million [10]. - The adjusted EBITDA loss expectation remains unchanged, projected to be in the range of DKK 75-80 million [10].